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T
issue transglutaminase (TG2) is one of a family of 
enzymes that covalently crosslink proteins by binding a 
glutamine in one protein with a lysine in another [1]. 
There is strong evidence that links the deregulated expression 
of TG2 to a variety of diseases, and although the exact role of 
TG2 in neurodegenerative diseases is unclear [2], in celiac 
disease (CD), TG2 catalyses the formation of immunogenic 
peptides that play a crucial role in disease development [3,4]. 
Although x-ray crystal structures of transglutaminases have 
been reported previously, the catalytic site was hidden due 
to the protein’s conformation. In this issue of PLoS Biology, a 
structure of TG2 is shown in which the enzyme is captured in 
its active state [5] with the catalytic site visible. This provides 
new insight into the mode of action of TG2 and offers novel 
opportunities for the development of TG2 inhibitors, which 
could have therapeutic applications. The paper also raises 
questions about what regulates TG2 activation and how TG2 
activation inﬂuences disease development.
The Role of TG2 in Celiac Disease
Patients with celiac disease  are intolerant to gluten proteins 
in wheat and related cereals [3,4]. In healthy individuals, the 
small intestine is lined with villi, which create a larger surface 
for the uptake of nutrients from food. In approximately 1% 
of the population in the Western Hemisphere, gluten induces 
inﬂammatory immune responses in the small intestine that 
lead to the disappearance of these villi. Malabsorption, 
retarded growth, diarrhea, and stomach ache can result, and 
these are the characteristic symptoms associated with CD [3,4].
CD typically develops in human leukocyte antigen (HLA)-
DQ2– and/or HLA-DQ8–positive individuals [3,4]. HLA 
molecules are receptors that speciﬁcally bind peptides and 
present these to the T cells of the immune system. When such 
peptides are derived from pathogens, an immune response is 
initiated to eradicate the pathogen. In the small intestine of 
patients with CD, erroneous T cell responses are made against 
gluten peptides bound to HLA-DQ2 and/or -DQ8 [6–9], 
as if they were pathogen derived, producing large amounts 
of interferon-gamma, which is a mediator of inﬂammation. 
However, it was previously unclear how HLA-DQ2 and HLA-
DQ8 bind gluten peptides. These molecules prefer peptides 
containing one or more negatively charged amino acids, yet 
gluten proteins are essentially devoid of these amino acids 
[10–12]. This paradox was resolved when it was observed that 
TG2 converts the glutamine residues in gluten peptides into 
glutamic acid, introducing the negative charges required 
for binding to HLA-DQ2 or -DQ8 [13,14] (Figure 1). In 
fact, gluten and TG2 have a special relationship: due to the 
amino acid composition of glutens (~30% Q, ~17% P, rich 
in F and Y), the sequences QXPF and QXPY (X is any amino 
acid except P) are common and the Q is a target for TG2 
[15]. TG2 modiﬁes gluten at several positions, leading to the 
formation of a large number of gluten peptides that can bind 
to HLA-DQ2 and/or -DQ8 and induce T cell responses [15–
17]. Together, these ﬁndings point to a crucial role of TG2 in 
the development of CD. 
Speciﬁc Contribution of Current Manuscript
Previous studies revealed that the GDP-bound form of 
TG2, which functions as a G-proteins within cells, is in a 
conformation where the active site is inaccessible and so the 
enzyme is catalytically inactive. In the current issue of PLoS
Biology, Pinkas and colleagues report the structure of the 
catalytically active form of TG2 [5]. To achieve this, they have 
captured the enzyme in complex with an inhibitor based on 
a gluten-derived substrate for TG2, the pentapeptide PQLPF. 
By replacing the Q with an electrophilic trap (6-diazo-5-oxo-
L-norleucine; don), a peptide was generated that covalently 
links itself to the cys residue in the active site of TG2, thus 
stabilizing it in its active state. 
The novel structure reveals that the active state is 
fundamentally different from the inactive state. The complete 
C-terminal beta1- and beta2-barrels, which cover the N-
terminal core domain in the catalytically inactive form, are in 
an extended conformation in the active form. This involves 
a 120-Å shift of the C-terminal residues, exposing the active 
site and the bound pentapeptide. This pentapeptide occupies 
one side of a hydrophobic tunnel that is bordered by two 
tryptophan residues and contains the catalytic cys residue, 
whereas the other side of the tunnel can accommodate 
the lysine residue, which will be covalently linked to the 
glutamine in the transamidation reaction. Several hydrogen 
bonds and hydrophobic interactions exist between TG2 and 
the pentapeptide PdonLPF. This is, in part, due to the trans 
conformation of the proline preceding the phenylalanine, 
which places the phenylalanine in a hydrophobic pocket. 
These interactions thus reveal why gluten peptides containing 
a QLPF or QLPY sequence are such good substrates for TG2. 
Importantly, a similar large conformational shift is now 
expected to occur in other transglutaminases, suggesting a 
general mechanism involved in the activation of this family of 
enzymes.
Perspective
As mentioned above, TG2 deamidates gluten peptides—a 
crucial step toward a full-blown T cell response against 
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gluten [3,4]. Moreover, it is well established that TG2-speciﬁc 
autoantibodies are speciﬁc indicators of CD, because they 
are almost exclusively found in CD patients. It has been 
shown that TG2 can crosslink itself to gluten, and it has 
been speculated that if such complexes are taken up by 
B cells—which express surface immunoglobulin speciﬁc 
for TG2—the TG2 complexes would be internalized and 
degraded intracellularly. This would release gluten peptides 
that subsequently can be bound to HLA-DQ2 molecules and 
presented to gluten-speciﬁc T cells, which would result in B 
cell activation and antibody production. In this way, gluten-
speciﬁc T cells would drive the production of TG2-speciﬁc 
antibodies [21]. In the current manuscript, Pinkas and 
colleagues [5] suggest an interesting alternative possibility: 
that the large conformational change associated with TG2 
activation may expose regions of TG2 that are normally 
shielded and that this leads to antibody formation. 
All of these ideas underscore the fact that TG2 activation 
is a critical step in disease development. But how is TG2 
activated and which circumstances promote a broad gluten-
speciﬁc T cell response? There is a large pool of extracellular 
TG2 in the intestine but no evidence that it is catalytically 
active [23]. Pinkas and colleagues [5] now speculate that in 
CD, this extracellular TG2 might be activated by ligands of 
the Toll-like receptor (TLR) receptors, which are pattern-
recognition receptors that alert the immune system to the 
presence of pathogens. However, TLR triggering is not unique 
to CD; it is part of the normal immune response to pathogens. 
So, transient TG2 activation is thus probably a natural and 
common phenomenon, as might be expected of an enzyme 
known to be involved in wound and tissue repair [1]. Similarly, 
evidence has been presented that indicates that certain gluten 
peptides might activate the innate immune system [24–26], 
which could likewise contribute to TG2 activation. But it is 
not clear why this would only occur in CD patients and not 
in healthy individuals. Further, most HLA-DQ2– and -DQ8–
positive individuals do not generate gluten-speciﬁc T cells or 
develop disease, despite the fact that they would be capable of 
generating deamidated gluten peptides if TG2 is active [3,4]. 
Thus, there must be something fundamentally different when 
doi:10.1371/journal.pbio.0050337.g001
Figure 1. HLA-DQ2 and HLA-DQ8 Are Expressed on So-Called Antigen-Presenting Cells
The function of antigen-presenting cells (APCs) is to bind peptides derived from pathogens and “present” these to the T cells of the immune system. 
T cells detect such HLA–peptide complexes through their T cell receptors. In celiac disease, T cells respond to gluten peptides bound to HLA-DQ2 or 
HLA-DQ8. Gluten-derived peptides (red diamond) bind only with low afﬁnity to HLA-DQ2 and HLA-DQ8, but TG2 can modify such peptides, which turns 
them into high-afﬁnity binders. Consequently, the HLA–gluten peptide complexes are more stable, which facilitates and enhances T cell responses to 
such peptides. 
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an individual does develop CD: what is the master switch that 
determines disease development? 
The key issue is that even though the majority of gluten-
reactive T cells in the intestine are speciﬁc for deamidated 
gluten, TG2 in the intestine is normally inactive, so no 
deamidated gluten peptides are generated. Then what 
activates TG2 and thereby initiates the deamidation of gluten? 
The answer may lie in the gluten-speciﬁc T cell response 
itself: some gluten-speciﬁc T cells respond to native gluten 
peptides [7,8,14], and such T cell responses could induce 
a low level of inﬂammation and the release of catalytically 
active TG2 from the damaged tissue [14] (Figure 1). Once 
this occurs, TG2 will generate a host of immunogenic gluten 
peptides. This may be particularly important in the early 
stages of disease development, because it would allow rapid 
epitope spreading: the diversiﬁcation of a limited response to 
a few (native) gluten peptides to a broad response involving 
a multitude of peptides [8]. Obviously, the development of 
such a T cell response takes weeks or even months, and early 
in that process, no symptoms will be apparent. The sustained 
exposure to gluten will generate a large gluten-speciﬁc 
T cell compartment in the intestine that will ultimately 
be dominated by T cells that are speciﬁc for the most 
immunogenic peptides, i.e., deamidated peptides with the 
best HLA-DQ–binding properties.
Ultimately, the question remains as to what drives the 
initial gluten-speciﬁc T cell response. Immune responses 
in the intestine are tightly regulated to avoid deleterious 
responses against harmless protein antigens. Infections in 
the intestine, however, are common, and these will force the 
mucosal immune system to take appropriate steps to eradicate 
the pathogens. This involves the polarization of the immune 
system toward inﬂammation. And this may provide a window 
in which inﬂammatory, gluten-speciﬁc T cell responses 
may escape from the tight regulation that suppresses such 
responses. Depending on the nature, duration, and/or 
persistence of the infections, such responses may become 
uncontrollable and lead to disease, whereas under more 
favorable conditions, they can be ultimately suppressed. It 
is likely that the outcome is inﬂuenced by genetics: a recent 
genome-wide association study has provided compelling 
evidence that a gene locus containing four genes, including 
IL2 and IL21, contributes to the chance of developing CD 
[27]. Clearly, the potential involvement of these immune-
related IL2 and IL21 genes is interesting, but because the 
risk associated is small [27], it will be a major undertaking to 
understand how such gene variants inﬂuence the chance of 
disease development. 
Finally, the structure of TG2 in its active form may allow 
the design of potent inhibitors for TG2. Such blockers could 
potentially be used for the treatment of diseases in which 
TG2 is thought to play a role, including neurodegenerative 
diseases and, of course, CD. Yet in CD, it is unclear if we 
would want to use them for this purpose, because a gluten-
free diet is an effective and entirely safe treatment for 
CD. Given the overall poor understanding of the multiple 
functions of TG2 and its role in wound repair, there might 
be unwanted side effects that limit the use of such blockers 
for treatment of CD. Conversely, for the treatment of 
neurodegenerative diseases, where the role of TG2 is less 
clear, the severity of the diseases may warrant the use of such 
inhibitors, despite potential side effects.
In conclusion, the tertiary twist associated with TG2 
activation opens doors that improve our understanding of 
the role of TG2 in disease development and may aid in the 
development of novel therapeutic options.  
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